Novartis has acquired IFM Due for $90 million after funding the company’s preclinical development of molecules targeting the STING pathway involved in inflammatory disorders. Novartis gains access to IFM Due’s research on cGAS, a protein that regulates the inflammatory response. The acquisition marks the third exit event for IFM Therapeutics, with Novartis potentially paying an additional $745 million based on research milestones. The acquisition comes as Ventus Therapeutics progresses with its own research on cGAS-STING pathway drugging. Ventus’s Phase 1 trial for VENT-03, a cGAS inhibitor, is ongoing with preliminary data expected in the second half of the year.
Source link
Novartis Pays $90M for Molecules That Could Take STING Out of Inflammation
